Koselugo (selumetinib) approved in the US for NF1
13 April 2020 07:00 BST Koselugo (selumetinib) approved in US for paediatricpatients with neurofibromatosis type 1 plexiform neurofibromas First medicine approved to treat this rare and debilitating genetic condition AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved the kinase inhibitor Koselugo (selumetinib) for the treatment of paediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable